• Avanir Pharmaceuticals Inc., of Aliso Viejo, Calif., said it filed a $35 million shelf registration with the Securities and Exchange Commission. The firm makes drugs for chronic conditions, including Zenvia (dextromethorphan hydrobromide-quinidine sulfate), an NMDA antagonist and sigma-1 agonist under investigation for diabetic peripheral neuropathic pain.

• Expression Pathology Inc., of Rockville, Md., said it received additional financing of $6.5 million to apply its Liquid Tissue proteomics technology in developing personalized medicine clinical assays that relate measurement of protein biomarkers of drug response and disease prognosis to specific patient treatment decisions. The financing was led exclusively by Abraxis BioScience Inc., of Los Angeles.